Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2026-01-01 @ 10:32 PM
Study NCT ID:
NCT05243693
Status:
RECRUITING
Last Update Posted:
2022-02-17
First Post:
2022-01-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma
Sponsor:
National Cancer Center, Korea
Organization:
Organization Data
Organization:
Class:
OTHER_GOV
Study ID:
NCC2020-0293
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER_GOV
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None